Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia).php on line 2
Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia)

LE WE PMID CA

Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia)

1252

Lipoproteine (Dys und Hyperlipoproteinaemie)

Avasimibe

CNS (Stroke BASKET)

Colesevelam

Ezetimibe

Fenofibrate

Fibrate

Implitapide

Kidney (Chronic renal failure)

Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia)

Niacin

Statin

Torcetrapib

1995 1	Hyperlipidemia: perspectives in diagnosis and treatment. [7716588] South Med J 88(4): 379-91 (1995)
1970 2	Classification of hyperlipidaemias and hyperlipoproteinaemias. [4930042] Bull World Health Organ 43(6): 891-915 (1970)
2008 3	Combination therapy in the management of mixed dyslipidaemia. [18324928] J Intern Med 263(4): 353-65 (2008)
2006 4	Familial hypercholesterolemia: a challenge of diagnosis and therapy. [16444917] Cleve Clin J Med 73(1): 57-64 (2006)
2006 5	Management of dyslipidaemias. [16973811] Heart 92(10): 1529-34 (2006)
2007 6	Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. [18200807] Vasc Health Risk Manag 3(6): 877-86 (2007)
2009 7	Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. [19604457] Health Technol Assess 13(34): 1-74, 75-118 (2009)
2000 8	Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. [10648253] Am J Clin Nutr 71(2): 412-33 (2000)
1983 9	Musculoskeletal disorders in patients with hyperlipidaemia. [6625701] Ann Rheum Dis 42(5): 519-23 (1983)
1979 10	The natural history and surgical significance of hyperlipemic abdominal crisis. [485615] Ann Surg 190(3): 401-8 (1979)
2003 11	Effective management of patients with dyslipidemia. [12597240] Am J Manag Care 9(2 Suppl): S39-58 (2003)
1979 12	Cellular pathology of homozygous familial hypercholesterolemia. [118674] Am J Pathol 97(2): 327-57 (1979)
2006 13	Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. [16403839] Am J Physiol Renal Physiol 290(2): F262-72 (2006)
2007 14	In the clinic. Dyslipidemia. [17785482] Ann Intern Med 147(5): ITC9-1-ITC9-16 (2007)
1970 15	The hyperlipoproteinemias. A simplified classification and approach to therapy. [4924875] Calif Med 112(5): 32-7 (1970)
2005 16	Managing abnormal blood lipids: a collaborative approach. [16286609] Circulation 112(20): 3184-209 (2005)
2007 17	Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. [17360973] Clin Cancer Res 13(7): 1971-8 (2007)
2006 18	Management of dyslipidemias in patients with diabetes and chronic kidney disease. [17699330] Clin J Am Soc Nephrol 1(5): 1090-9 (2006)
2005 19	Management of hereditary dyslipidaemia; the paradigm of autosomal dominant hypercholesterolaemia. [16189547] Eur J Hum Genet 13(12): 1247-53 (2005)
2004 20	Management of dyslipidaemia. [15253984] Heart 90(8): 949-55 (2004)
2003 21	Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. [12668600] Hum Mol Genet 12 Spec No 1(-): R75-88 (2003)
2008 22	Recognition and management of dyslipidemia in children and adolescents. [18697860] J Clin Endocrinol Metab 93(11): 4200-9 (2008)
2007 23	Update on dyslipidemia. [17483372] J Clin Endocrinol Metab 92(5): 1581-9 (2007)
2003 24	Medical management of hyperlipidemia/dyslipidemia. [12788840] J Clin Endocrinol Metab 88(6): 2445-61 (2003)
2000 25	Hyperlipidemia: diagnostic and therapeutic perspectives. [10852435] J Clin Endocrinol Metab 85(6): 2089-112 (2000)
1999 26	Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. [10552997] J Lipid Res 40(11): 1933-49 (1999)
1984 27	Pathogenesis of hyperlipoproteinemia. [6397565] J Lipid Res 25(13): 1611-8 (1984)
2008 28	Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. [18949717] J Nephrol 21(5): 635-44 (2008)
2004 29	Drug treatment of hyperlipidemia in women. [15138247] JAMA 291(18): 2243-52 (2004)
2007 30	Safety of aggressive lipid management. [17466224] J Am Coll Cardiol 49(17): 1753-62 (2007)
1995 31	Lipid-lowering therapy in patients with renal disease. [7564077] Kidney Int 48(1): 188-98 (1995)
1991 32	Lipid abnormalities in renal disease. [2002630] Kidney Int 39(1): 169-83 (1991)
2005 33	Management of mixed hyperlipidaemia. [15781431] Eur Heart J 26(9): 856-7 (2005)
2010 34	Frequency and determinants of lipid testing in ischemic stroke and transient ischemic attack: findings from get with the guidelines-stroke. [20035071] Stroke 41(2): 232-8 (2010)
2006 35	Lipid-lowering drugs. [16568248] Cell Mol Life Sci 63(10): 1165-78 (2006)
2005 36	Lipid-modifying drugs. [15777144] Med J Aust 182(6): 286-9 (2005)
2008 37	Management of dyslipidaemia - evidence and practical recommendations. [18592069] Aust Fam Physician 37(7): 521-7 (2008)
2009 38	Dietary intervention to lower serum cholesterol. [19521587] Aust Fam Physician 38(6): 424-9 (2009)
2011 39	Lipid-lowering therapy: who can benefit? [21915170] Vasc Health Risk Manag 7(-): 525-34 (2011)
2010 40	Low high-density lipoprotein cholesterol: current status and future strategies for management. [21127701] Vasc Health Risk Manag 6(-): 979-96 (2010)
2010 41	Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. [20234782] Vasc Health Risk Manag 6(-): 73-85 (2010)
2010 42	Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. [20531954] Vasc Health Risk Manag 6(-): 351-62 (2010)
2009 43	Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. [20016845] Vasc Health Risk Manag 5(-): 901-8 (2009)
2007 44	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. [17969377] Vasc Health Risk Manag 3(4): 467-79 (2007)
2009 45	Dyslipidemia in chronic kidney disease: pathogenesis and intervention. [19776689] Pol Arch Med Wewn 119(7-8): 487-92 (2009)
2004 46	Managing dyslipidemia in chronic kidney disease. [15482558] J Gen Intern Med 19(10): 1045-52 (2004)
2003 47	Weight of the evidence in statin clinical trials: comparing the results. [12884938] J Am Osteopath Assoc 103(7 Suppl 3): S4-11 (2003)
2009 48	Management of dyslipidemia in children. [19995441] Diabetol Metab Syndr 1(1): 26 (2009)
2010 49	Primary prevention of CVD: treating dyslipidaemia. [21418693] Clin Evid (Online) 2010(): (2010)
PMC 50	Treatment of dyslipidemia. [24669298] F1000Prime Rep 6(): (2014)
PMC 51	Mipomersen (Kynamro): A Novel Antisense Oligonucleotide Inhibitor for the Management of Homozygous Familial Hypercholesterolemia. [24669178] P T 39(2):119-22 (2014)
PMC 52	Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels. [23413428] Arterioscler Thromb Vasc Biol 33(4):687-93 (2013)
PMC 53	The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. [24749106] Glob Cardiol Sci Pract 2013(4):343-7 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Lipoprotein (Dyslipoproteinemia Hyperlipoproteinemia).php on line 92